Funding Inequities

Funding Inequities Your story in the December 12 issue of The Scientist concerning NIH funding had the title, “The Rich Get Richer” (page 19). So what’s new? Many of us interacting with the system have known of the institutionalized inequity of the system for years. The reason why these institutions have monopolized the bulk of NIH dollars is because they have seeded the study sections with their own people and friends. The cruel joke is that many people inside the exclusive

Written byRonald Paque
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Your story in the December 12 issue of The Scientist concerning NIH funding had the title, “The Rich Get Richer” (page 19). So what’s new? Many of us interacting with the system have known of the institutionalized inequity of the system for years. The reason why these institutions have monopolized the bulk of NIH dollars is because they have seeded the study sections with their own people and friends. The cruel joke is that many people inside the exclusive club, including NIH bureaucrats, have the audacity to labelthis socalled “peer review” as fair and equitable.

John Lein’s [vice president for health sciences at the University of Washington] statements reinforce the altitude of long-standing intellectual arrogance among the “club” by the rather outrageous assumption that most of the nation’s’ excellence and biological-brain-power is concentrated in only, 10 institutions. This is sheer nonsense.

I disagree with Lein’s argument that for the U.S. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies